Acreage Holdings, Inc.

The stock remains in a deep long-term downtrend, still below its 200-day average and well under its prior year high. The setup is a low-priced, high-beta recovery chart, but the broader regime still favors sellers until price can reclaim the longer moving averages.

Street sentiment is mildly constructive with a Buy consensus, but the target at 0.40 sits above the current tape by a wide margin. There have been no recent rating changes, so the view looks stable rather than improving.

Earnings history has been consistently weak, with 0 of the last 7 quarters beating expectations and several large misses. Next-year estimates still point to a smaller loss, so shareholders should watch for any narrowing in EPS losses and whether revenue stabilizes after a 32.9% YoY decline.

No discretionary insider buying or selling stands out. Recent activity is dominated by award and vesting-related grants to executives and directors, which reads as compensation flow rather than a conviction signal.

Profitability remains under pressure, with ROE at -135.6% and EPS TTM at -0.85. Gross margin is 49.5%, but revenue fell 32.9% year over year and the balance sheet carries $232.8 million of debt against $13.6 million of cash.

As a cannabis operator in specialty pharmaceuticals, it competes on brand, retail reach, and cultivation execution rather than scale alone. The valuation remains distressed versus the broader healthcare group, with a sub-$5 million market cap and a negative earnings profile.